PyInvesting

Market research

KILITCH.NSE Kilitch Drugs (India) Limited

NSE INR Healthcare

Latest close

Loading market data…

Test a moving-average rule with historical data.

Market cap
6B
P/E ratio
18.45
Analyst target
466
Dividend yield
Not available
Beta
0.36

Community

Investor discussion

1 comment

Admin profile picture
Admin

5 years, 5 months ago

Kilitch Drugs (India) Limited is currently in a long term uptrend where the price is trading 47.6% above its 200 day moving average.

From a valuation standpoint, the stock is 56.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.1.

Kilitch Drugs (India) Limited's total revenue rose by 27.6% to $203M since the same quarter in the previous year.

Its net income has increased by 134.3% to $22M since the same quarter in the previous year.

Finally, its free cash flow grew by 784.5% to $365M since the same quarter in the previous year.

Based on the above factors, Kilitch Drugs (India) Limited gets an overall score of 5/5.